Zim Laboratories (NSE:ZIMLAB) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
76 GF Score
Price ₹124.90
GF Value ₹102.87
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Zim Laboratories's operating assets for the quarter that ended in Mar. 2026 was ₹5,116 Mil. Zim Laboratories's operating liabilities for the quarter that ended in Mar. 2026 was ₹1,168 Mil. Zim Laboratories's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Zim Laboratories's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Zim Laboratories Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Scaled Net Operating Assets Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.75 1.00 0.82 0.84

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:ZIMLAB vs ZTS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Scaled Net Operating Assets falls into.


NSE:ZIMLAB
76GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Zim Laboratories's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(5115.852-1168.367)/4722.743
=0.84

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5393.871 - 278.019
=5115.852

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2432.33 - 424.203 - 839.76
=1168.367

Zim Laboratories's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(5115.852-1168.367)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5393.871 - 278.019
=5115.852

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2432.33 - 424.203 - 839.76
=1168.367

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score

Get the complete analysis for NSE:ZIMLAB

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.90
Price
₹102.87
GF Value